26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03075553 (ClinicalTrials.gov) | May 17, 2017 | 1/3/2017 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) | Blastic Plasmacytoid Dendritic Cell Neoplasm;Hepatosplenic T-Cell Lymphoma;HTLV-1 Infection;NK-Cell Lymphoma, Unclassifiable;Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative;Recurrent Adult T-Cell Leukemia/Lymphoma;Recurrent Anaplastic Large Cell Lymphoma;Recurrent Angioimmunoblastic T-cell Lymphoma;Recurrent Enteropathy-Associated T-Cell Lymphoma;Recurrent Mycosis Fungoides;Refractory Adult T-Cell Leukemia/Lymphoma;Refractory Anaplastic Large Cell Lymphoma;Refractory Angioimmunoblastic T-cell Lymphoma;Refractory Enteropathy-Associated T-Cell Lymphoma;Refractory Mycosis Fungoides;Refractory Nasal Type Extranodal NK/T-Cell Lymphoma;Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Other: Laboratory Biomarker Analysis;Biological: Nivolumab | Mayo Clinic | National Cancer Institute (NCI) | Terminated | 18 Years | N/A | All | 12 | Phase 2 | United States |
| 2 | NCT02631746 (ClinicalTrials.gov) | February 21, 2017 | 15/12/2015 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma | Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection;Lymphomatous Adult T-Cell Leukemia/Lymphoma;Smoldering Adult T-Cell Leukemia/Lymphoma | Other: Laboratory Biomarker Analysis;Biological: Nivolumab;Other: Pharmacogenomic Study | National Cancer Institute (NCI) | NULL | Completed | 18 Years | N/A | All | 3 | Phase 2 | United States |